Regulatory submission for the treatment of anaemia of chronic kidney disease based on the ASCEND phase III clinical trial programme, consisting of five trials that all met their primary efficacy and safety endpoints in non-dialysis and dialysis…Original Article
You may also like
UroGen Submits Completed UGN-102 NDA Seeking Approval...
FDA Accepts LEO Pharma’s Filing of Delgocitinib...
Iterum Therapeutics Provides Update on FDA Advisory...
AbbVie Submits Biologics License Application to the...
PTC Therapeutics Announces FDA Acceptance for Filing...
Stealth BioTherapeutics Announces Positive Vote from...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.